Compare Incyte Corporation (INCY) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Upwork Inc — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Upwork Inc trades at $9.04 (market cap $1.15B). The key difference: Incyte Corporation is far larger — about 20.1× Upwork Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| INCY | UPWK | |
|---|---|---|
Market Cap | $23.11B | $1.15B |
Sector | Health | Industrials |
52-Week High | $118.52 | $22.11 |
52-Week Low | $67.38 | $7.84 |
Enterprise Value | $19.13B | $952.17M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
UPWK trades at $9.33, up 2.98% today, with a neutral technical signal and mixed earnings history including recent EPS misses. Revenue grew to $787.78M in 2025 with strong profitability margins (net margin 13.81%), but cash flow turned negative. Analyst consensus is a Buy with a $10.67 target, though legal investigations and competitive pressures pose headwinds.
The stock offers value with low P/E (11.19) and EV/EBITDA (5.96), but risks include ongoing fraud probes and gig economy volatility. Upside depends on execution amid AI integration initiatives, while downside is cushioned by solid balance sheet liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
